Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Hunter Cochran, Raya Saba, Ningying Wu, Neha Mehta-Shah, Armin Ghobadi, John DiPersio, Amanda Cashen

Blood (2025) 146 (Supplement 1): 1860.

https://doi.org/10.1182/blood-2025-1860

Published: 2025

Journal Articles

Waning Long Term Efficacy of COVID-19 Post-Transplant Vaccination for Prevention of COVID-19 Adverse Events in Transplant and Cellular Therapy (TCT) Patients

Rahul Ramaswamy, Laith Fakhoury, Peter Zhao, Ningying Wu, Feng Gao, Geoffrey L. Uy, John F. DiPersio, Zachary D. Crees

Blood (2024) 144 (Supplement 1): 3532.

https://doi.org/10.1182/blood-2024-204417

Published: 2024

Journal Articles

Phase II Trial of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and B-Cell Non-Hodgkin Lymphomas: Results of Safety Lead in

Raya Saba, Neha Mehta-Shah, Armin Ghobadi, John F. DiPersio, Amanda F Cashen, Ningying Wu

Blood (2023) 142 (Supplement 1): 6245.

https://doi.org/10.1182/blood-2023-174109

Published: 2023

Journal Articles

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Ningying Wu, PhD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Camille N. Abboud, MD

Blood (2017) 130 (Supplement 1): 3204.

https://doi.org/10.1182/blood.V130.Suppl_1.3204.3204

Published: 2017

Journal Articles

A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma

Tzu-Fei Wang, MD, Mark A. Fiala, BS, CCRP, Ningying Wu, PhD, Theresa Fletcher, Camille N. Abboud, MD, Amanda F. Cashen, MD, John F. Dipersio, MD, PhD, Geoffrey L. Uy, MD, Peter Westervelt, MD, PhD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MD

Blood (2013) 122 (21): 5492.

https://doi.org/10.1182/blood.V122.21.5492.5492

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Waning Long Term Efficacy of COVID-19 Post-Transplant Vaccination for Prevention of COVID-19 Adverse Events in Transplant and Cellular Therapy (TCT) Patients

Phase II Trial of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and B-Cell Non-Hodgkin Lymphomas: Results of Safety Lead in

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Waning Long Term Efficacy of COVID-19 Post-Transplant Vaccination for Prevention of COVID-19 Adverse Events in Transplant and Cellular Therapy (TCT) Patients

Phase II Trial of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and B-Cell Non-Hodgkin Lymphomas: Results of Safety Lead in

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only